![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CT45A1 |
Gene summary for CT45A1 |
![]() |
Gene information | Species | Human | Gene symbol | CT45A1 | Gene ID | 541466 |
Gene name | cancer/testis antigen family 45 member A1 | |
Gene Alias | CT45 | |
Cytomap | Xq26.3 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q5HYN5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
541466 | CT45A1 | HCC1_Meng | Human | Liver | HCC | 5.89e-29 | 9.34e-02 | 0.0246 |
541466 | CT45A1 | S014 | Human | Liver | HCC | 9.69e-59 | 1.72e+00 | 0.2254 |
541466 | CT45A1 | S015 | Human | Liver | HCC | 1.15e-57 | 2.22e+00 | 0.2375 |
541466 | CT45A1 | S016 | Human | Liver | HCC | 3.08e-74 | 2.15e+00 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Esophagus | ESCC | ![]() |
Skin | AK | ![]() |
Skin | SCCIS | ![]() |
Skin | cSCC | ![]() |
Thyroid | HT | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00344702 | Liver | HCC | ncRNA processing | 293/7958 | 395/18723 | 4.26e-38 | 6.76e-35 | 293 |
GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
GO:00311231 | Liver | HCC | RNA 3'-end processing | 81/7958 | 116/18723 | 2.27e-09 | 6.32e-08 | 81 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CT45A1 | SNV | Missense_Mutation | novel | c.23T>G | p.Val8Gly | p.V8G | Q5HYN5 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-A8-A0A6-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | epirubicin | CR |
CT45A1 | SNV | Missense_Mutation | novel | c.163N>A | p.Ala55Thr | p.A55T | Q5HYN5 | protein_coding | tolerated(0.68) | benign(0.001) | TCGA-D8-A1JG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
CT45A1 | SNV | Missense_Mutation | novel | c.526G>T | p.Asp176Tyr | p.D176Y | Q5HYN5 | protein_coding | tolerated(0.1) | possibly_damaging(0.474) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CT45A1 | SNV | Missense_Mutation | novel | c.125N>A | p.Ala42Glu | p.A42E | Q5HYN5 | protein_coding | tolerated(0.71) | probably_damaging(0.917) | TCGA-AG-3902-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CT45A1 | SNV | Missense_Mutation | novel | c.544A>G | p.Lys182Glu | p.K182E | Q5HYN5 | protein_coding | tolerated(1) | benign(0) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CT45A1 | SNV | Missense_Mutation | novel | c.124N>T | p.Ala42Ser | p.A42S | Q5HYN5 | protein_coding | tolerated(0.27) | possibly_damaging(0.828) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CT45A1 | SNV | Missense_Mutation | novel | c.549N>T | p.Lys183Asn | p.K183N | Q5HYN5 | protein_coding | tolerated(0.06) | benign(0.229) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CT45A1 | SNV | Missense_Mutation | novel | c.11N>C | p.Lys4Thr | p.K4T | Q5HYN5 | protein_coding | deleterious(0.01) | benign(0.266) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
CT45A1 | SNV | Missense_Mutation | novel | c.519N>T | p.Met173Ile | p.M173I | Q5HYN5 | protein_coding | tolerated(0.13) | benign(0) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
CT45A1 | SNV | Missense_Mutation | novel | c.546N>T | p.Lys182Asn | p.K182N | Q5HYN5 | protein_coding | deleterious(0) | benign(0.08) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |